natgillin/translations-raw huggingface dataset:
for a compound of Formula I where R5 is hetCyc4 where hetCyc4 is a nitrogen radical, reacting a corresponding compound of formula V-a with a compound having the formula hetCyc4-H; or 
u slučaju spoja Formule I, gdje je R5 hetCyc4, gdje je hetCyc4 dušični radikal, reakciji odgovarajućeg spoja formule V-a [image] sa spojem formule hetCyc4-H; ili
for a compound of Formula I where R5 is hetAr3 and hetAr3 is a nitrogen radical, reacting a corresponding compound of formula V-a with a compound having the formula hetAr3 -H in the presence of a base; or 
u slučaju spoja Formule I, gdje je R5 hetAr3, a hetAr3 je dušični radikal, reakciji odgovarajućeg spoja formule V-a [image] sa spojem formule hetAr3-H, u prisutnosti baze; ili
for a compound of Formula I where R5 is hetAr3- or hetAr5- where hetAr3 and hetAr5 are carbon radicals, reacting a corresponding compound of formula V-b with a compound having the formula hetAr3-H or hetAr5-H, respectively, in the presence of a palladium catalyst and a base and optionally in the presence of a ligand; or 
u slučaju spoja Formule I, gdje je R5 hetAr3- ili hetAr5-, gdje su hetAr3 i hetAr5 ugljični radikali, reakciji odgovarajućeg spoja formule V-b [image] sa spojem formule hetAr3-H odnosno hetAr5-H, u prisutnosti paladijskog katalizatora i baze, te izborno u prisutnosti liganda; ili
for a compound of Formula I where R5 is hetCyc5C(=O)-, reacting a corresponding compound having the formula VII with a compound having the formula hetCyc5-H in the presence of a base; or 
u slučaju spoja Formule I, gdje je R5 hetCyc5C(=O)-, reakciji odgovarajućeg spoja formule VII [image] sa spojem formule hetCyc5-H, u prisutnosti baze; ili
for a compound of Formula I where R5 has the structure: reacting a corresponding compound having the formula VIII where R5b is respectively, with formaldehyde in the presence of a reducing agent; or 
u slučaju spoja Formule I, gdje R5 ima strukturu: [image], reakciji odgovarajućeg spoja formule VIII [image], gdje je R5b [image], s formaldehidom, u prisutnosti reducensa; ili
for a compound of Formula I where R5 is R'R"NC(=O)-, reacting a corresponding compound of formula IX with a compound having the formula R'R"NH in the presence of a coupling agent; or 
u slučaju spoja Formule I, gdje je R5 R′R″NC(=O)-, reakciji odgovarajućeg spoja formule IX [image] sa spojem formule R′R″NH, u prisutnosti kondenzacijskog sredstva; ili
for a compound of Formula I wherein R5 is an oxadiazole substituent having the formula: where Rg is H or Me, cyclizing a corresponding compound having the formula X in the presence of trimethoxymethane or triethoxyethane, respectively; or 
u slučaju spoja Formule I, gdje je R5 oksadiazolski supstituent formule: [image], gdje je Rg H ili Me, cikliziranju odgovarajućeg spoja formule X [image], u prisutnosti trimetoksimetana odnosno trietoksietana; ili
for a compound of formula I wherein R5 is 1,3,4-thiadiazol-2-yl, cyclizing a corresponding compound having the formula XI in the presence of P2S5; or 
u slučaju spoja formule I, gdje je R5 1,3,4-tiadiazol-2-il, cikliziranju odgovarajućeg spoja formule XI [image], u prisutnosti P2S5; ili
for a compound of Formula I wherein R1 is hetAr1CH2- wherein hetAr1 is substituted with hetCyc1 where hetCyc1 is a nitrogen radical, reacting a compound having the formula XIII with a compound having the formula hetCyc1-H in the presence of a reducing agent; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 supstituiran s hetCyc1, gdje je hetCyc1 dušični radikal, reakciji spoja formule XIII [image] sa spojem formule hetCyc1-H, u prisutnosti reducensa; ili
for a compound of Formula I wherein R2 is ethyl, coupling a corresponding compound having the formula XIV with a compound having the formula (CH2=CH)BF3K in the presence of a palladium catalyst and a base, followed by reduction of the 3-vinyl-1H-indazolyl intermediate; or 
u slučaju spoja Formule I, gdje je R2 etil, kondenziranju odgovarajućeg spoja formule XIV [image] sa spojem formule (CH2=CH)BF3K, u prisutnosti paladijskog katalizatora i baze, uz naknadnu redukciju 3-vinil-1H-indazolilnog međuprodukta; ili
for a compound of Formula I wherein R1 is hetAr1CH2-, wherein hetAr1 is pyridyl substituted with -CH2NMe2 or ethyl, coupling a corresponding compound having the formula XVI-a where L1 is a leaving group or atom, with a compound having the formula ME2NCH2BF3K or (CH2=CH)BF3K, respectively, in the presence of a palladium catalyst and a base when coupling with (CH2=CH)BF3K, followed by reduction of the vinyl group when compound XVI-a is coupled with (CH2=CH)BF3K; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 piridil, supstituiran s -CH2NMe2 ili etilom, kondenziranju odgovarajućeg spoja formule XVI-a [image], gdje je L1 izlazna skupina ili atom, sa spojem formule ME2NCH2BF3K odnosno (CH2=CH)BF3K, u prisutnosti paladijskog katalizatora i baze kod kondenziranja s (CH2=CH)BF3K, uz naknadnu redukciju vinilne skupine kod kondenziranja spoja XVI-a s (CH2=CH)BF3K; ili
for a compound of Formula I wherein R1 is (N-1-3C alkyl)pyridinonyl-CH2-optionally substituted with one or more substituted independently selected from (1-6C)alkyl, coupling a corresponding compound having the formula XVI with (1-6C alkyl)-L2 where L2 is a leaving group or atom in the presence of a base; or 
u slučaju spoja Formule I, gdje je R1 (N-1-3C alkil)piridinonil-CH2-, izborno supstituiran s jednim ili više supstituenata, koje se neovisno bira između (1-6C)alkila, kondenziranju odgovarajućeg spoja formule XVI [image] s (1-6C alkil)-L2, gdje je L2 izlazna skupina ili atom, u prisutnosti baze; ili
for a compound of Formula I wherein R1 is hetAr1CH2-, wherein hetAr1 is pyridyl substituted with hetCyc2a(1-2C)alkoxy, coupling a corresponding compound having the formula XVI with a compound having the formula hetCyc2a(1-2C)OH in the presence of a coupling reagent; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 piridil, supstituiran s hetCyc2a(1-2C)alkoksi, kondenziranju odgovarajućeg spoja formule XVI [image] sa spojem formule hetCyc2a(1-2C)OH, u prisutnosti kondenzacijskog reagensa; ili
for a compound of Formula I wherein R1 is hetAr1CH2-, wherein hetAr1 is pyridyl substituted with hetCyc1- where hetCyc1- is a nitrogen radical, coupling a corresponding compound having the formula XVI-a where L1 is a leaving group or atom, with a corresponding compound having the formula hetCyc1-H in the presence of a palladium catalyst, a ligand and a base; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 piridil, supstituiran s hetCyc1-, gdje je hetCyc1- dušični radikal, kondenziranju odgovarajućeg spoja formule XVI-a [image], gdje je L1 izlazna skupina ili atom, s odgovarajućim spojem formule hetCyc1-H, u prisutnosti paladijskog katalizatora, liganda i baze; ili
for a compound of Formula I wherein R1 is hetAr1CH2-, wherein hetAr1 is pyridyl substituted with dimethylamino(2-4C)alkoxy, reacting a compound having the formula XVI-b where m is 1, 2 or 3, with formaldehyde in the presence of a base; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 piridil, supstituiran s dimetilamino(2-4C)alkoksi, reakciji spoja formule XVI-b [image], gdje je m 1, 2 ili 3, s formaldehidom, u prisutnosti baze; ili
for a compound of Formula I wherein R1 is hetAr1CH2-, wherein hetAr1 is pyridyl substituted with hetCyc2a(1-2C)alkoxy and hetCyc2a has an N-methyl substituted ring N atom, reacting a corresponding compound having the formula XVI-c where n is 1 or 2 and Y is a hetCyc2a having a ring NH group, with formaldehyde in the presence of a reducing agent; or 
u slučaju spoja Formule I, gdje je R1 hetAr1CH2-, gdje je hetAr1 piridil, supstituiran s hetCyc2a(1-2C)alkoksi, a hetCyc2a ima N-metilom supstituirani N atom u prstenu, reakciji odgovarajućeg spoja formule XVI-c [image], gdje je n 1 ili 2, a Y je hetCyc2a, koji u prstenu ima skupinu NH, s formaldehidom, u prisutnosti reducensa; ili
for a compound of Formula I wherein R5 is hetCyc6CH2- where hetCyc6 is a nitrogen radical, coupling a corresponding compound having the formula XVII where L2 is a leaving group with a compound having the formula hetCyc6-H in the presence of a base; or 
u slučaju spoja Formule I, gdje je R5 hetCyc6CH2-, gdje je hetCyc6 dušični radikal, kondenziranju odgovarajućeg spoja formule XVII [image], gdje je L2 izlazna skupina, sa spojem formule hetCyc6-H, u prisutnosti baze; ili
for a compound of Formula I wherein R5 is hetCyc6(1-4Calkyl)- where hetCyc6 a nitrogen radical, reacting a corresponding compound having the formula XIX where n is 0, 1, 2 or 3, and L3 is a leaving group, with a corresponding compound having the formula hetCyc6H in the presence of an activating agent; or 
u slučaju spoja Formule I, gdje je R5 hetCyc6(1-4C alkil)-, gdje je hetCyc6 dušični radikal, reakciji odgovarajućeg spoja formule XIX [image], gdje je n 0, 1, 2 ili 3, a L3 je izlazna skupina, s odgovarajućim spojem formule hetCyc6-H, u prisutnosti aktivatora; ili
for a compound of Formula I wherein R5 is CH3C(=O)-, coupling a corresponding compound having the formula V-b with a compound having the formula in the presence of a palladium catalyst and a ligand, followed by treatment with acid; or 
u slučaju spoja Formule I, gdje je R5 CH3C(=O)-, kondenziranju odgovarajućeg spoja formule V-b [image] sa spojem formule [image], u prisutnosti paladijskog katalizatora i liganda, uz naknadnu obradu kiselinom; ili
A medicament delivery device containing a composition according to any one of claims 1 to 8, said device adapted to deliver individual or successive doses of said composition, each individual or successive dose containing no more than 80mg of artemesinin or derivative thereof, preferably no more than 10mg of artemesinin or derivative thereof. A delivery device according to claim 9 or claim 10 wherein said device comprises a pump spray. 
Uređaj za primjenu lijeka naznačen time što sadrži kompoziciju prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je navedeni uređaj prilagođen za primjenu pojedinačnih ili uzastopnih doza navedene kompozicije, pri čemu pojedinačna ili uzastopna doza sadrži ne više od 80 mg artemetra ili arteetra, poželjno ne više od 10 mg artmemetra ili arteetra.
The combination of claim 1, 2 or 3 wherein the additional therapeutic agent is R7128. 
Kombinacija prema patentnom zahtjevu 1, 2 ili 3 gdje je dodatno terapeutsko sredstvo antivirusno sredstvo inhibitor polimeraze R7128.
Procedure for the preparation of naphthalene derivatives of structure I, according to claims 1 and 2, that carry in R1 an acid or amino terminal group characterized by the reaction of the acylating agent, N -hydroxysuccinimide ester of 4-(1-naphthylamino)-4-oxobutanoic acid of claim 4, with compounds having primary amino groups, such as aliphatic diamines, linear or branched, and polyfunctional amines such as a-amino acids, thioamines, aminoalcohols and aminocarboxylic acids, in presence or not of an organic base, in DMF or 1,4-dioxane as solvent. 
Postupak za pripremu derivata naftalena strukture I, prema zahtjevima 1 i 2, koji u R1 nose neku kiselinsku ili amino terminalnu skupinu, naznačen reakcijom acilacijskog sredstva, N-hidroksisukcinamid estera 4-(1-naftalimino)-4-oksobutanoične kiseline prema zahtjevu 4, pri čemu spojevi imaju primarne amino skupine kao što su alifatski diamini, linearni ili razgranati, i polifunkcionalne amine kao što su a-amino kiseline, tioamini, aminoalkoholi i aminokarboksilne kiseline, u prisutnosti neke organske baze ili bez nje, u DMF-u ili 1,4-dioksanu kao otapalu.
The procedure of the claim 5 where naphthalene derivatives are obtained through a one-pot technique, characterized by the reaction of the 4-(1-naphthylamino)-4-oxobutanoic acid, with NHS in presence of DCC, to obtain in situ the intermediate N -hydroxysuccinimide ester of 4-(1-naphthylamino)-4-oxobutanoic acid of claim 4, and its immediate reaction with an excess of diamine or an aminocarboxylic acid, at room temperature and DMF or 1, 4 - dioxane as solvent. 
Postupak prema zahtjevu 5 gdje se derivati naftalena dobiju pomoću neke tehnike „u jednom loncu“, naznačen reakcijom 4-(1-naftilamino)- 4- oksobutanoične kiseline s NHS u prisutnosti DCC, da bi se in situ dobio prijelazni N-hidroksisukdinimid ester 4-(1-naftilamino)-4-oksobutanoične kiseline prema zahtjevu 4, i njegovom neposrednom reakcijom s viškom diamina ili aminokarboksilne kiseline na sobnoj temperaturi te s DMF-om ili 1, 4–dioksanom kao otapalom.
represents a hydrogen atom, an aryl which is an unsubstituted phenyl or naphthyl, a substituted aryl which is a phenyl or a naphthyl substituted with one or more groups of atoms chosen from an alkyl, an alkoxy, a halogen, a hydroxyl, a cyano, a trifluoromethyl and a nitro, an alkyl, a cycloalkyl, a cycloalkylalkyl or a cycloalkylalkylalkyl, 
Spoj opće formule (I) [image], naznačen time što: predstavlja atom vodika, aril, koji je nesupstituirani fenil ili naftil, supstituirani aril, koji je fenil ili naftil, supstituiran s jednom ili više skupina atoma, koje se bira između alkila, alkoksi, halogena, hidroksila, cijano, trifluormetila i nitro, alkil, cikloalkil, cikloalkilalkil ili cikloalkilalkilalkil;
represents an aralkyl which is an alkyl substituted with an aryl or a substituted aralkyl which is an alkyl substituted with a substituted aryl, 
predstavlja aralkil, koji je alkil supstituiran s arilom, ili supstituirani aralkil, koji je alkil supstituiran sa supstituiranim arilom;
represents a heteroaralkyl which is an alkyl substituted with heteroaryl or a substituted heteroaralkyl which is an alkyl substituted with a substituted heteroaryl, 
predstavlja heteroaralkil, koji je alkil supstituiran s heteroarilom, ili supstituirani heteroaralkil, koji je alkil supstituiran sa supstituiranim heteroarilom;
n, m is equal to 1 or 2; and also the corresponding salts and enantiomers. 
n i m iznose 1 ili 2; a također i odgovarajuće soli i enantiomeri.
X represents an oxygen atom or a sulfur atom, 
X predstavlja atom kisika ili atom sumpora;
and also the corresponding salts and enantiomers. 
a također i odgovarajuće soli i enantiomeri.
and also the respective salts and enantiomers thereof. 
a također i njihove odgovarajuće soli i enantiomeri.
inflammatory diseases of the digestive apparatus, especially including the intestine (and particularly the colon in the case of irritable bowel syndrome, ulcero-haemorrhagic rectocolitis or Crohn's disease); pancreatitis, hepatitis (acute and chronic), inflammatory bladder pathologies and gastritis; 
– upalnih bolesti probavnog sustava, osobito uključujući crijeva (a osobito debelog crijeva u slučaju sindroma iritabilnih crijeva, ulcero-hemoragijskog rektokolitisa ili Crohnove bolesti), pankreatitisa, hepatitisa (akutnog i kroničnog), upalnih patoloških promjena na mokraćnom mjehuru i gastritisa;
inflammatory diseases of the urogenital apparatus and especially glomeruloneph ritis; 
– upalnih bolesti urogenitalnog sustava, a osobito glomerulonefritisa;
inflammatory diseases of the cardiac apparatus and especially pericarditis and myocarditis and diseases including those for which inflammation is an underlying factor (such as atherosclerosis, transplant atherosclerosis, peripheral vascular diseases, inflammatory vascular diseases, intermittent claudication or limping, restenosis, strokes, transient ischaemic attacks, myocardial ischaemia and myocardial infarction), hypertension, hyperlipidaemia, coronary diseases, unstable angina (or angina pectoris), thrombosis, platelet aggregation induced by thrombin and/or the consequences of thrombosis and/or of the formation of atheroma plaques; 
– upalnih bolesti srčanožilnog sustava, a osobito perikarditisa i miokarditisa i bolesti koje uključuju one kod kojih je upala osnovni čimbenik (poput ateroskleroze, ateroskleroze presatka, bolesti perifernih krvnih žila, upalnih bolesti krvnih žila, povremena šepavost ili hramanje, restenoza, inzulti, prolazni ishemični napadaji, ishemija miokarda i infarkt miokarda), hipertenzija, hiperlipidemija, bolesti koronarnih arterija, nastabilna angina (ili angina pektoris), tromboza, agregacija trombocita pod utjecajem trombina i/ili posljedice tromboze i/ili formiranja ateromnih naslaga;
inflammatory diseases of the respiratory and ORL apparatus, especially including asthma, acute respiratory distress syndrome, hayfever, allergic rhinitis and chronic obstructive pulmonary disease, or allergies; 
– upalnih bolesti dišnog i ORL sustava, osobito uključujući astmu, sindrom akutnog respiratornog distresa, peludnu groznicu, alergijski rinitis i kroničnu opstruktivnu plućnu bolest, ili alergije;
inflammatory diseases of the central nervous system and especially Alzheimer's disease and any other form of dementia, Parkinson's disease, Creutzfeldt-Jakob disease, multiple sclerosis and meningitis; 
– upalnih bolesti središnjeg živčanog sustava, a osobito Alzheimerove bolesti i bilo kojeg drugog oblika demecije, Parkinsonove bolesti, Creutzfeldt-Jakobove bolesti, multiple skleroze i meningitisa;
inflammatory diseases of the skin, and especially urticaria, scleroderma, contact dermatitis, atopic dermatitis, psoriasis, ichthyosis, acne and other forms of folliculitis, rosacea and alopecia; 
– upalnih bolesti kože, a osobito koprivnjače, skleroderme, kontaktnog dermatitisa, atopičnog dermatitisa, psorijaze, ihtioze, akni i drugi oblika folikulitisa, rozaceja i alopecije;
autoimmune diseases and especially lupus erythematosus, thyroid complaints, autoimmune diseases of the adrenal glands and autoimmune gastritis, vitiligo and alopecia areata; 
– autoimunih bolesti, a osobito eritemskog lupusa, tireoidnih tegoba, autoimunih bolesti nadbubrežnih žlijezda i autoimunog gastritisa, vitiliga i alopecije areate;
modulating pigmentation, and the treatment of: diseases with pigmentation disorders and especially benign dermatoses such as vitiligo, albinism, melasma, lentigo, ephelides, melanocytic naevus and all post-inflammatory pigmentations; and also pigmented tumours such as melanomas and their local (permeation molecules), regional or systemic metastases; 
– moduliranja pigmentacije, te liječenja bolesti s poremećajem pigmentacije, a osobito dobroćudnih dermatoza, poput vitiliga, albinizma, melazme, lentiga, sunčanih pjega, melanocitnog madeža i svih poslijeupalnih pigmentacija; a također i pigmentiranih tumora, poput melanoma i njihovih lokalnih (permeacijskih molekula), regionalnih ili sistemnih metastaza;
. bouts of dermatosis with photosensitivity and especially light-aggravated dermatoses (for example lupus erythematosus, recurrent herpes, congenital poikilodermal or telangiectatic conditions with photosensitivity (Bloom's syndrome, Cockayne's syndrome or Rothmund-Thomson syndrome), actinic lichen planus, actinic granuloma, superficial disseminated actinic porokeratosis, acne rosacea, juvenile acne, bullous dermatosis, Darier's disease, lymphoma cutis, psoriasis, atopic dermatitis, contact eczema, follicular mucinosis, erythema multiforme, fixed drug eruption, cutaneous lymphocytoma, reticular erythematous mucinosis, and melasma), 
• epizoda dermatoze s fotoosjetljivošću, a osobito ◦ dermatoza pogoršanih pod utjecajem svjetla (primjerice eritemskog lupusa, povratnog herpesa, urođenih poikilodermnih ili telangiektatskih stanja s fotoosjetljivošću (Bloomovog sindroma, Cockayneovog sindroma ili Rothmund-Thomsonovog sindroma), aktiničnog lišaja, aktiničnog granuloma, površinske diseminirane aktinične porokeratoze, rozacejskih akni, juvenilnih akni, bulozne dermatoze, Darierove bolesti, kutanog limfoma, psorijaze, atopičnog dermatitisa, kontaktnog ekcema, folikularne mucinoze, multiformnog eritema, fiksnog lijekovima uzrokovanog osipa, kutanog limfocitoma, retikularne eritemne mucinoze, te melazme);
dermatoses with photosensitivity by deficiency of the protective system with anomalies of melanin formation or distribution (for example oculocutaneous albinism, phenylketonuria, hypopituitarism, vitiligo and piebaldism) with deficiency of the DNA repair systems (for example xeroderma pigmentosum and Cockayne's syndrome), 
◦ dermatoza s fotoosjetljivošću zbog manjkavosti u sustavu zaštite s anomalijama u sintezi ili raspodjeli melanina (primjerice okulokutanog albinizma, fenilketonurije, hipopituitarizma, vitiliga i piebaldizma) uz manjkavosti u sustavima za popravak DNA (primjerice pigmentne kseroderme i Cockayneovog sindroma);
dermatoses with photosensitivity via metabolic anomalies, for instance cutaneous porphyria (for example tardive cutaneous porphyria, mixed porphyria, erythropoietic protoporphyria, congenital erythropoietic porphyria (Giinther's disease), and erythropoietic coproporphyria), pellagra or pellagroid erythema (for example pellagra, pellagroid erythemas and tryptophan metabolism disorders); 
◦ dermatoza s fotoosjetljivošću zbog metaboličkih anomalija, primjerice kutane porfirije (primjerice tardivne kutane porfirije, miješane porfirije, eritropoetske protoporfirije, urođene eritropoetske porfirije (Güntherove bolesti), te eritropoetske koproporfirije), pelagre ili pelagroidnog eritema (primjerice pelagre, pelagroidnih eritema i poremećaja u metabolizmu triptofana);
modifying the colour of the skin or head hair and bodily hair, and especially by tanning the skin by increasing melanin synthesis or bleaching it by interfering with melanin synthesis, but also by preventing the bleaching or greying of head hair or bodily hair (for example canities and piebaldism); and also modifying the colour of head hair and bodily hair in cosmetic indications. 
– modificiranja boje kože ili kose i tjelesnih dlaka, a osobito tamnjenja kože pojačavanjem sinteze melanina, ili njenog izbljeđivanja ometanjem sinteze melanina, no također i sprječavanja izbljeđivanja ili sjeđenja kose ili tjelesne dlake (primjerice prosjedosti i piebaldizma); a također i modificiranja boje kose i tjelesnih dlaka kod kozmetičkih indikacija.
modifying the sebaceous function and especially for treating: 
– modificiranja funkcije lojnih žlijezda i osobito kod liječenja:
. hyperseborrhoea complaints and especially acne, seborrhoeic dermatitis, greasy skin and greasy hair, hyperseborrhoea in Parkinson's disease and epilepsy and hyperandrogenism; 
• hiperseboroičnih tegoba, a osobito akni, seboroičnog dermatitisa, masne koža i masne kose, hiperseboreje kod Parkinsonove bolesti i epilepsije, te hiperandrogenizma;
. regulating the benign or malignant proliferation of sebocytes and the sebaceous glands; 
• reguliranja dobroćudne ili zloćudne proliferacije sebocita i lojnih žlijezda;
. inflammatory complaints of the pilosebaceous follicles and especially acne, boils, carbuncles and folliculitis; 
• upalnih tegoba dlačno-lojnih folikula, a osobito akni, furunkula, karbunkula i folikulitisa;
cancer and in particular lung cancer, prostate cancer, bowel cancer, breast cancer, ovarian cancer, bone cancer or angiogenesis disorders including the formation or growth of solid tumours. 
– raka, a osobito raka pluća, raka prostate, raka crijeva, raka dojke, raka jajnika, raka kosti ili poremećaja angiogeneze, uključujući nastanak ili rast čvrstih tumora.
skin diseases and especially urticaria, scleroderma, contact dermatitis, atopic dermatitis, psoriasis, ichthyosis, acne and other forms of folliculitis, rosacea and alopecia. 
– bolesti kože i osobito koprivnjače, skleroderme, kontaktnog dermatitisa, atopičnog dermatitisa, psorijaze, ihtioze, akni i drugih oblika folikulitisa, rozaceje i alopecije.
diseases with pigmentation disorders and especially benign dermatoses such as vitiligo, albinism, melasma, lentigo, ephelides, melanocytic naevus and all post-inflammatory pigmentations; and also pigmented tumours such as melanomas and their local (permeation molecules), regional or systemic metastases. 
– bolesti s poremećajem pigmentacije, a osobito dobroćudnih dermatoza, poput vitiliga, albinizma, melazme, lentiga, sunčanih pjega, melanocitnog madeža i svih poslijeupalnih pigmentacija; a također i pigmentiranih tumora, poput melanoma i njihovih lokalnih (permeacijskih molekula), regionalnih ili sistemnih metastaza.